Nuveen’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Nuveen’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-915,934	Closed	-$3.48M	–	3438
2020 Q1	$3.48M	Buy	915,934 +266,409	+41%	+$1.15M	﹤0.01%	1904
2019 Q4	$3.31M	Buy	649,525 +4,835	+0.7%	+$25.6K	﹤0.01%	2205
2019 Q3	$3.26M	Buy	644,690 +9,675	+2%	+$48.2K	﹤0.01%	2171
2019 Q2	$3.92M	Buy	+635,015	New	+$3.06M	﹤0.01%	2116

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Nuveen's PGNX Position: Q2 2020 in Review

Nuveen sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 915,934 shares — an estimated $3.48M sold.

Nuveen first reported a position in PGNX in Q2 2019 and held it in 4 quarters. The position peaked at $3.92M in Q2 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Nuveen reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Nuveen sold 915,934 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $3.48M.
Nuveen first reported a position in Progenics Pharmaceuticals Inc in Q2 2019 and held it in 4 quarters.
Nuveen's Progenics Pharmaceuticals Inc position peaked at $3.92M in Q2 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Nuveen's 13F filing for Q2 2020, filed 14 Aug 2020.